165 related articles for article (PubMed ID: 10508428)
1. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle.
Owa T; Yoshino H; Okauchi T; Yoshimatsu K; Ozawa Y; Sugi NH; Nagasu T; Koyanagi N; Kitoh K
J Med Chem; 1999 Sep; 42(19):3789-99. PubMed ID: 10508428
[TBL] [Abstract][Full Text] [Related]
2. New analogues of the anticancer E7070: synthesis and pharmacology.
Laconde G; Pommery N; Depreux P; Berthelot P; Hénichart JP
J Enzyme Inhib Med Chem; 2003 Apr; 18(2):89-94. PubMed ID: 12943191
[TBL] [Abstract][Full Text] [Related]
3. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
4. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide.
Owa T; Yokoi A; Yamazaki K; Yoshimatsu K; Yamori T; Nagasu T
J Med Chem; 2002 Oct; 45(22):4913-22. PubMed ID: 12383017
[TBL] [Abstract][Full Text] [Related]
5. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
Yokoi A; Kuromitsu J; Kawai T; Nagasu T; Sugi NH; Yoshimatsu K; Yoshino H; Owa T
Mol Cancer Ther; 2002 Feb; 1(4):275-86. PubMed ID: 12467223
[TBL] [Abstract][Full Text] [Related]
6. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
Ozawa Y; Sugi NH; Nagasu T; Owa T; Watanabe T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Eur J Cancer; 2001 Nov; 37(17):2275-82. PubMed ID: 11677118
[TBL] [Abstract][Full Text] [Related]
7. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Van Kesteren C; Beijnen JH; Schellens JH
Anticancer Drugs; 2002 Nov; 13(10):989-97. PubMed ID: 12439332
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents.
Owa T; Yoshino H; Yoshimatsu K; Nagasu T
Curr Med Chem; 2001 Oct; 8(12):1487-503. PubMed ID: 11562278
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells.
Fukuoka K; Usuda J; Iwamoto Y; Fukumoto H; Nakamura T; Yoneda T; Narita N; Saijo N; Nishio K
Invest New Drugs; 2001; 19(3):219-27. PubMed ID: 11561678
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.
Owa T; Yoshino H; Okauchi T; Okabe T; Ozawa Y; Hata Sugi N; Yoshimatsu K; Nagasu T; Koyanagi N; Kitoh K
Bioorg Med Chem Lett; 2002 Aug; 12(16):2097-100. PubMed ID: 12127512
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antiproliferative and apoptotic activities of N-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents.
Abbassi N; Chicha H; Rakib el M; Hannioui A; Alaoui M; Hajjaji A; Geffken D; Aiello C; Gangemi R; Rosano C; Viale M
Eur J Med Chem; 2012 Nov; 57():240-9. PubMed ID: 23072738
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
13. QSAR of antineoplastics V: Exploration of receptor interaction sites of antitumor N-(7-indolyl)benzenesulfonamides targeting GI phase using electrotopological state atom index.
Roy K; Pal DK; Sengupta C
Drug Des Discov; 2001; 17(3):207-18. PubMed ID: 11469751
[TBL] [Abstract][Full Text] [Related]
14. Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle.
Li Y; Shan F; Wu JM; Wu GS; Ding J; Xiao D; Yang WY; Atassi G; Léonce S; Caignard DH; Renard P
Bioorg Med Chem Lett; 2001 Jan; 11(1):5-8. PubMed ID: 11140731
[TBL] [Abstract][Full Text] [Related]
15. Indisulam: an anticancer sulfonamide in clinical development.
Supuran CT
Expert Opin Investig Drugs; 2003 Feb; 12(2):283-7. PubMed ID: 12556221
[TBL] [Abstract][Full Text] [Related]
16. QSAR of antineoplastics IV: Hansch analysis of N-(7-indolyl)benzenesulfonamides against KB human nasopharynx carcinoma, colon 38 murine adenocarcinoma and P388 murine leukemia cell lines.
Roy K; Pal DK; De AU; Sengupta C
Drug Des Discov; 2001; 17(3):199-206. PubMed ID: 11469750
[TBL] [Abstract][Full Text] [Related]
17. Anticancer and antiviral sulfonamides.
Scozzafava A; Owa T; Mastrolorenzo A; Supuran CT
Curr Med Chem; 2003 Jun; 10(11):925-53. PubMed ID: 12678681
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of aragusterol a (YTA0040), a potent anti-tumor marine steroid targeting the G(1) phase of the cell cycle.
Fukuoka K; Yamagishi T; Ichihara T; Nakaike S; Iguchi K; Yamada Y; Fukumoto H; Yoneda T; Samata K; Ikeya H; Nanaumi K; Hirayama N; Narita N; Saijo N; Nishio K
Int J Cancer; 2000 Dec; 88(5):810-9. PubMed ID: 11072253
[TBL] [Abstract][Full Text] [Related]
19. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors.
Owa T; Okauchi T; Yoshimatsu K; Sugi NH; Ozawa Y; Nagasu T; Koyanagi N; Okabe T; Kitoh K; Yoshino H
Bioorg Med Chem Lett; 2000 Jun; 10(11):1223-6. PubMed ID: 10866386
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
